Ultragenyx Pharmaceutical (RARE) Receives Analyst Rating

Ultragenyx Pharmaceutical (RARE) has an average broker rating of 1.23, which is interpreted as a Strong Buy, as rated by 13 equity analysts. Nonetheless, 11 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Ultragenyx Pharmaceutical (RARE) : Currently there are 12 street experts covering Ultragenyx Pharmaceutical (RARE) stock. The most bullish and bearish price target for the stock is $125 and $74 respectively for the short term. The average price target of all the analysts comes to $93.58. The estimated standard deviation from the target is $14.


Also, Piper Jaffray initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE). In the latest research report, Piper Jaffray announces the target price to $70 per share. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. The rating by the firm was issued on July 7, 2016.

Ultragenyx Pharmaceutical (NASDAQ:RARE): After opening at $72.3, the stock dipped to an intraday low of $71.71 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $74.73 and the buying power remained strong till the end. The stock closed at $74.19 for the day, a gain of 2.86% for the day session. The total traded volume was 522,112. The stocks close on the previous trading day was $72.13.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *